Literature DB >> 9868693

Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination.

S Matsumura1, A E Simor.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9868693     DOI: 10.1086/517755

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  15 in total

1.  Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents.

Authors:  S O Matsumura; L Louie; M Louie; A E Simor
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

2.  Enterococcal endocarditis: can we win the war?

Authors:  Jose M Munita; Cesar A Arias; Barbara E Murray
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

3.  Vancomycin-Resistant Enterococcus: Infectious Endocarditis Treatment.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-06       Impact factor: 3.725

4.  Increasing Antimicrobial Resistance: Therapeutic Implications for Enterococcal Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-10       Impact factor: 3.725

Review 5.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

6.  Quinupristin/dalfopristin: the first available macrolide-lincosamide-streptogramin antibiotic.

Authors:  C Gurk-Turner
Journal:  Proc (Bayl Univ Med Cent)       Date:  2000-01

7.  Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis.

Authors:  R Patel; M S Rouse; K E Piper; J M Steckelberg
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 8.  Treatment options for vancomycin-resistant enterococcal infections.

Authors:  Peter K Linden
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 9.  Management of multidrug-resistant enterococcal infections.

Authors:  C A Arias; G A Contreras; B E Murray
Journal:  Clin Microbiol Infect       Date:  2010-06       Impact factor: 8.067

10.  In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model.

Authors:  George P Allen; Raymond Cha; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.